Z. Reguiaï

1.3k total citations
60 papers, 834 citations indexed

About

Z. Reguiaï is a scholar working on Immunology, Rheumatology and Dermatology. According to data from OpenAlex, Z. Reguiaï has authored 60 papers receiving a total of 834 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Immunology, 20 papers in Rheumatology and 18 papers in Dermatology. Recurrent topics in Z. Reguiaï's work include Psoriasis: Treatment and Pathogenesis (17 papers), Autoimmune Bullous Skin Diseases (12 papers) and Urticaria and Related Conditions (12 papers). Z. Reguiaï is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (17 papers), Autoimmune Bullous Skin Diseases (12 papers) and Urticaria and Related Conditions (12 papers). Z. Reguiaï collaborates with scholars based in France, Switzerland and United States. Z. Reguiaï's co-authors include Philippe Bernard, Thierry Tabary, Florent Grange, G. Perceau, Fabien Vitry, F. Maccari, Coralie Barbe, M.‐L. Sigal, Frank Antonicelli and E. Mahé and has published in prestigious journals such as Annals of the Rheumatic Diseases, Journal of the American Academy of Dermatology and British Journal of Dermatology.

In The Last Decade

Z. Reguiaï

50 papers receiving 811 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Z. Reguiaï France 17 365 318 283 246 200 60 834
Giacomo Caldarola Italy 23 281 0.8× 298 0.9× 93 0.3× 648 2.6× 570 2.9× 93 1.2k
Birte Sporbeck Germany 12 226 0.6× 181 0.6× 139 0.5× 170 0.7× 239 1.2× 23 584
Maher Issa United States 19 151 0.4× 493 1.6× 130 0.5× 120 0.5× 163 0.8× 26 965
P. Bravard France 10 394 1.1× 246 0.8× 217 0.8× 112 0.5× 101 0.5× 28 587
M Bala Türkiye 8 134 0.4× 581 1.8× 76 0.3× 479 1.9× 232 1.2× 28 1.1k
Zoltán Szekanecz Hungary 12 150 0.4× 279 0.9× 27 0.1× 144 0.6× 57 0.3× 24 653
Jose Andrés Román Ivorra Spain 12 116 0.3× 472 1.5× 40 0.1× 149 0.6× 45 0.2× 76 687
Mary Carns United States 16 609 1.7× 111 0.3× 21 0.1× 182 0.7× 177 0.9× 34 923
Annelies E. van Ede Netherlands 10 65 0.2× 551 1.7× 344 1.2× 107 0.4× 32 0.2× 19 1.1k
Claire Bethune United Kingdom 13 131 0.4× 150 0.5× 388 1.4× 156 0.6× 18 0.1× 25 683

Countries citing papers authored by Z. Reguiaï

Since Specialization
Citations

This map shows the geographic impact of Z. Reguiaï's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Z. Reguiaï with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Z. Reguiaï more than expected).

Fields of papers citing papers by Z. Reguiaï

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Z. Reguiaï. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Z. Reguiaï. The network helps show where Z. Reguiaï may publish in the future.

Co-authorship network of co-authors of Z. Reguiaï

This figure shows the co-authorship network connecting the top 25 collaborators of Z. Reguiaï. A scholar is included among the top collaborators of Z. Reguiaï based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Z. Reguiaï. Z. Reguiaï is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Reguiaï, Z., et al.. (2023). Efficacity of dupilumab in severe idiopathic cold urticaria: a case report. Journal of Dermatological Treatment. 34(1). 2182620–2182620. 3 indexed citations
3.
Misery, L., Jason Shourick, Julien Sénéschal, et al.. (2020). Use of mind‐body practices by patients with psoriasis: results from a study on 2562 patients. Journal of the European Academy of Dermatology and Venereology. 35(4). e305–e307. 2 indexed citations
4.
Richard, M.‐A., C. Paul, Gérard de Pouvourville, et al.. (2020). Out‐of‐pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross‐sectional, non‐comparative, multicentre study. Journal of the European Academy of Dermatology and Venereology. 35(4). 912–918. 4 indexed citations
5.
Phan, C., Alain Beauchet, J. Mazereeuw‐Hautier, et al.. (2019). Evaluation of Children with Psoriasis from the BiPe Cohort: Are Patients Using Biotherapies in Real Life Eligible for Phase III Clinical Studies?. Pediatric Drugs. 21(3). 169–175. 6 indexed citations
6.
Fougerousse, Anne‐Claire, Pierre‐André Bécherel, V. Pallure, et al.. (2019). Combining Omalizumab with Another Biotherapy. Acta Dermato Venereologica. 99(4). 448–449. 9 indexed citations
7.
Jaussaud, R., et al.. (2017). Traitement du lupus érythémateux par le bélimumab en pratique courante : étude rétrospective de 15 malades. Annales de Dermatologie et de Vénéréologie. 145(1). 5–12. 2 indexed citations
8.
Paul, C., J.‐P. Lacour, A. Khemis, et al.. (2016). Évaluation de la tolérance du sécukinumab chez les patients atteints de psoriasis en plaques modéré à sévère : résultats à 2 ans. Annales de Dermatologie et de Vénéréologie. 143(12). S192–S192.
9.
Michel, M., et al.. (2016). Ustekinumab dans le rhumatisme psoriasique après échec des anti-TNFα en pratique courante. Therapies. 71(3). 281–286. 3 indexed citations
10.
Reguiaï, Z., et al.. (2015). AB0778 Vespa Study: Association Between Spondyloarthritis and Hidradenitis Suppurativa. Annals of the Rheumatic Diseases. 74. 1159–1159. 1 indexed citations
11.
Bachmeyer, Claude, Z. Reguiaï, L. Peuvrel, et al.. (2013). Toxicité cutanée des anti-EGFR (epidermal growth factor receptor) : algorithme thérapeutique du groupe français PROCUR. Bulletin du Cancer. 100(5). 417–426. 1 indexed citations
12.
Peuvrel, L., Claude Bachmeyer, Z. Reguiaï, et al.. (2012). Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors. Supportive Care in Cancer. 20(5). 909–921. 40 indexed citations
13.
Mahé, E., Z. Reguiaï, H. Barthélémy, et al.. (2012). Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross‐sectional study. Journal of the European Academy of Dermatology and Venereology. 28(2). 151–159. 25 indexed citations
14.
Reguiaï, Z., et al.. (2009). Calcinose pseudotumorale de localisation inhabituelle chez un patient hémodialysé. Annales de Dermatologie et de Vénéréologie. 136(4). 350–354. 13 indexed citations
15.
Bouché, Olivier, et al.. (2009). Biothérapies ciblées en cancérologie digestive : prise en charge de leurs effets secondaires. Gastroentérologie Clinique et Biologique. 33(4). 306–322. 8 indexed citations
16.
Bernard, Philippe, Z. Reguiaï, Emmanuelle Tancrède‐Bohin, et al.. (2009). Risk Factors for Relapse in Patients With Bullous Pemphigoid in Clinical Remission. Archives of Dermatology. 145(5). 537–42. 84 indexed citations
17.
Bézier, M., Z. Reguiaï, Fabien Vitry, Franck Broly, & Philippe Bernard. (2008). Thiopurine S-methyltransferase genotypic analysis in autoimmune bullous diseases.. PubMed. 18(5). 512–7. 7 indexed citations
18.
Reguiaï, Z., Nicolas Jovenin, Philippe Bernard, & Christian Derancourt. (2008). Melanoma, Past Severe Sunburns and Multiple Solar Lentigines of the Upper Back and Shoulders. Dermatology. 216(4). 330–336. 8 indexed citations
19.
Reguiaï, Z., et al.. (2008). Pemphigus vulgaire de l’enfant. Annales de Dermatologie et de Vénéréologie. 135(12). 843–847. 2 indexed citations
20.
Reguiaï, Z., et al.. (2007). Une ulcération palpébrale nécrotique. La Revue de Médecine Interne. 29(5). 410–411. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giacomo Caldarola Breakdown of academic impact, for papers by Birte Sporbeck Breakdown of academic impact, for papers by Maher Issa Breakdown of academic impact, for papers by P. Bravard Breakdown of academic impact, for papers by M Bala Breakdown of academic impact, for papers by Zoltán Szekanecz Breakdown of academic impact, for papers by Jose Andrés Román Ivorra Breakdown of academic impact, for papers by Mary Carns Breakdown of academic impact, for papers by Annelies E. van Ede Breakdown of academic impact, for papers by Claire Bethune
Rankless by CCL
2026